|August 3, 2017
Contact: Whitney Ray
Phone: (850) 245-0150
|en Español||Print Version||Tweet|
TALLAHASSEE, Fla—Attorney General Pam Bondi’s Office announced that Florida joined 28 other states and the federal government to settle allegations that Celgene Corporation, a biopharmaceutical company, engaged in a variety of marketing schemes to promote the off-label use of two drugs, Thalomid® and Revlimid®. The company also allegedly promoted the drugs by paying kickbacks to providers in order to induce the providers to prescribe the drugs.
As part of the settlement, Celgene will pay the states and the federal government $280 million, of which more than $20 million will go to state Medicaid programs. The payment to the Medicaid programs will resolve civil allegations that the company unlawfully marketed the two drugs, causing false claims to be submitted to government health care programs. Florida will receive more than $1.4 million as part of the settlement.
The settlement stems from a whistleblower lawsuit, U.S., et al, ex. rel. Beverly Brown v Celgene Corporation, Civ. Action No. CV10-03165, filed in the United States District Court for the Central District of California.
To view a copy of the settlement, click here.
The Florida Attorney General's Medicaid Fraud Control Unit investigates and prosecutes providers that intentionally defraud the state's Medicaid program through fraudulent billing practices. Medicaid fraud essentially steals from Florida's taxpayers. From Jan. 2011 to the present, Attorney General Bondi's MFCU has obtained more than $700 million in settlements and judgments. Additionally, the MFCU investigates allegations of patient abuse, neglect, and exploitation in facilities receiving payments under the Medicaid program. In 2017, the MFCU was awarded the Inspector General's Award for Excellence in Fighting Fraud, Waste and Abuse. This award is presented annually to the nation’s top MFCU by the U.S. Department of Health and Human Services Office of Inspector General.